Enabling Rapid Cell Line Screening to reach results faster

Monoclonal antibody (mAb) based therapeutics have allowed the development of targeted and revolutionary treatment approaches. These laboratory-engineered biotherapeutics have improved treatment outcomes in patients with a variety of conditions, including cancer, autoimmune diseases, and even transplantation rejections. The development and accessibility of mAbs is currently limited owing to the significant financial and time investments required for cell line establishment. Building reproducible, scalable and cost-effective mAb cell line establishment processes is necessary to continue the momentum behind these critical therapies.

During this process, identification of antigen-specific, highly productive, and optimally growing clones requires screening hundreds to thousands of cell lines. The number of clones requires enabling a rapid identification of cell lines for further development. However, conventional analytical methods like bio-layer interferometry (BLI) and liquid chromatography-mass spectrometry (LC-MS) for cell line screening are time-consuming. They may also require intensive hands-on involvement for ensuring the accuracy and reliability of experimental results.

Rapid high-throughput screening and automated methods for IgG quantification allow for faster identification of cell lines worth developing. For instance, Beckman Coulter Life Sciences’ Valita Titer IgG Quantitation assay, paired with Molecular Devices SpectraMAX iD5 plate reader, offers an optimized platform for rapid and accurate IgG quantification in crude samples. The platform significantly reduces the time required for cell line screening by eliminating the need for sample preparation or purification, guaranteeing reliable and consistent results.

Incorporating Molecular Devices’ SoftMax Pro software with the Valita Titer—SpectraMAX iD5 workflow can reduce the screening time even further. The SoftMax Pro software minimizes setup time for cell line detection and reduces hands-on time by automating standard curve fitting and sample quantitation. Overall, a combination of Valita Titer, SpectraMAX iD5, and SoftMax Pro software offers a high level of consistency across various screens, beyond time savings and ease of use.

Pushing the boundaries of technology, these high-throughput, low-cost solutions for cell line screening can unlock new opportunities during drug discovery. To move faster in cell line development, contact an expert at the Life Sciences companies of Danaher today.